๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Langfang
Clinical trial register · China

Clinical Trials in Langfang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences4 AstraZeneca2 Beijing QL Biopharmaceutical Co.,Ltd2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.2 Novo Nordisk A/S2
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Langfang

35 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)
NCT07812597Obesity
DrugsZovaglutide·Semaglutide
Beijing QL Biopharmaceutical Co.,Ltd
Phase 2
210
Beijing, Huizhou, Handan, Langfang, Harbin, Nanyang, Yichang, Changde
2026-10-12
Recruiting
A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity
NCT07747857Type 2 Diabetes Mellitus Combined With Overweight or Obesity
DrugTQF3250
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
72
Fuzhou, Guangzhou, Langfang, Luoyang, Wuhan, Yichang, Changsha, Nanjing
2026-08-25
Recruiting
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
NCT07797335Type 2 Diabetes, Cardiovascular Risk
DrugZenagamtide
Novo Nordisk A/S
Phase 3
1,778
Hefei, Beijing, Chongqing, Shenzhen, Cangzhou, Langfang, Shijiazhuang, Kaifeng
2026-08-24
Recruiting
Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis
NCT07678931Seasonal Allergic Rhinitis (SAR)
DrugStapokibart
Chengdu Kangnuoxing Biopharma,Inc.
Phase 3
136
Beijing, Langfang, Baoding, Cangzhou, Shijiazhuang, Zhangjiakou, Zhengzhou, Baotou
2026-08-13
Recruiting
Evaluation of Fecal Multi-target Biomarkers in the Screening of Digestive Tract Cancers
NCT07600125Gastric Cancer, Colorectal Cancer
Xijing Hospital
Observational
5,000
Xi'an, Dalian, Hami, Heze, Jinan, Langfang, Liuโ€˜an, Qingdao
2026-08-10
Not yet open
SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma
NCT07749859Advanced Unresectable Hepatocellular Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
80
Langfang
2026-08
Recruiting
A Phase I Trial of GW01-200 Tablets in Subjects With Advanced Tumors
NCT07629258Advanced Tumors
Groovy Medicine (Hangzhou) Ltd.
Phase 1
100
Beijing, Langfang, Hangzhou
2026-07-17
Recruiting
Adjuvant Moderately Hypofractionated Intensity-modulated Radiotherapy for Cervical Cancer
NCT07684508Hypofractionated Radiotherapy, Intensity-modulated Radiotherapy, Cervical Cancers
Manni Huang
Not applicable
154
Beijing, Langfang
2026-07-10
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
NCT07664553Type 2 Diabetes Mellitus
DrugElecoglipron
AstraZeneca
Phase 3
600
Changsha, Hefei, Huai'an, Langfang, Liangyugang, Luoyang, Nanjing, Nanyang
2026-07-08
Recruiting
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
NCT07662213Type 2 Diabetes Mellitus
DrugsElecoglipron·Semaglutide
AstraZeneca
Phase 3
1,200
Changsha, Hefei, Huai'an, Langfang, Liangyugang, Luoyang, Nanjing, Nanyang
2026-07-06
By invitation
Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin Icodec
NCT07658417Diabetes Mellitus, Type 2
DrugInsulin icodec
Novo Nordisk A/S
Observational
216
Beijing, Chongqing, Lanzhou, Jiangmen, Langfang, Harbin, Shiyan, Huai'an
2026-07-02
Recruiting
An Early-stage Clinical Trial to Evaluate the Safety, Absorption, and Disposition of YR001 Ointment Following Topical Application on the Skin of Healthy Chinese Subjects
NCT07673458Health Adult Subjects
Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Phase 1
18
Langfang
2026-06-22
Recruiting
Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation
NCT07444372Obstructive Sleep Apnea, Sleep Disorder (Disorder), Atrial Fibrillation (AF), Sleep Disordered Breathing (SDB)
Beijing Anzhen Hospital
Not applicable
658
Beijing, Fuzhou, Zhangzhou, Nanning, Langfang, Shijiazhuang, Xingtai, Harbin
2026-05-12
Recruiting
Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis
NCT07398859Seasonal Allergic Rhinitis
DrugTQH2722
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 2
300
Beijing, Chongqing, Baoding, Cangzhou, Langfang, Shijiazhuang, Zhangjiakou, Zhengzhou
2026-03-19
Not yet open
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome
NCT07375524Primary Sjรถgren Syndrome
DrugESG206
Shanghai Escugen Biotechnology Co., Ltd
Phase 2
40
Beijing, Xiamen, Guilin, Langfang, Changde, Changsha, Zhuzhou, Xuzhou
2026-03-01
Not yet open
A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies
NCT07476378Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Follicular, Lymphoma, Mantle-Cell, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
69
Langfang
2026-03
Recruiting
A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07327229Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
DrugsATG-022·Pembrolizumab KEYTRUDA·Capox
Antengene Biologics Limited
Phase 1/2
132
Hefei, Beijing, Fuzhou, Xiamen, Lanzhou, Langfang, Shijiazhuang, Anyang
2026-02-27
Recruiting
Platform Study of VSV-Based Recombinant Oncolytic Viruses for the Treatment of Advanced Malignant Tumors
NCT07656116Advanced Solid Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
27
Langfang
2026-01-29
Active, closed
Efficacy and Safety of ZT006 in Overweight and Obese Participants
NCT07230132Overweight , Obesity
Beijing QL Biopharmaceutical Co.,Ltd
Phase 2
184
Handan, Langfang, Harbin, Luoyang, Chenzhou, Yueyang, Nanjing, Jinan
2025-12-12
Active, closed
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2
NCT07263776Acute Ischemic Stroke
DrugTocilizumab
Capital Medical University
Phase 3
692
Suzhou, Zhangzhou, Qinzhou, Langfang, Qinhuangdao, Tangshan, Harbin, Anyang
2025-12-05
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Pfizer
Phase 2/3
982
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Baoding, Langfang
2025-10-03
Recruiting
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
NCT07200375Diffuse Large B-Cell Lymphoma
DrugGlofitamab
Hoffmann-La Roche
Observational
300
Langfang, Tianjin, Beijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan
2025-09-29
Not yet open
A Phase III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis
NCT07146126Seasonal Allergic Rhinitis, SAR
Prime Gene Therapeutics Co., Ltd.
Phase 3
600
Beijing, Lanzhou, Baoding, Cangzhou, Langfang, Shijiazhuang, Daqing, Harbin
2025-09-15
Recruiting
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
NCT07145229Acute Gouty Arthritis, Gout Flare, Gout Flares, Acute Gout Flare
DrugsABP-745 A·ABP-745 B·Colchicine
Atom Therapeutics Co., Ltd
Phase 2
380
Beijing, Nanning, Langfang, Wuhan, Xiangtan, Zhuzhou, Huai'an, Pingxiang
2025-08-26
Recruiting
A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT07292714Chronic Obstructive Pulmonary Disease COPD
Drug9MW1911
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 2
360
Chizhou, Hefei, Lanzhou, Huizhou, Jiangmen, Qingyuan, Zunyi, Langfang
2025-07-15
Not yet open
Optimal Standard Treatment Selection for Solid Tumor Patients by Biologically-informed Multi-agent System
NCT06824792Advanced Solid Tumors
NING LI
Phase 4
3,000
Langfang
2025-03-01
Not yet open
Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)
NCT06859931Systemic Lupus Erythematosus
DrugTQB3702
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
120
Bengbu, Hefei, Beijing, Lanzhou, Guangzhou, Shenzhen, Nanning, Langfang
2025-03
Recruiting
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine
NCT06754605Respiratory Syncytial Virus
Sinocelltech Ltd.
Phase 1/2
480
Langfang, Luzhou
2025-02-06
Active, closed
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
NCT06628310Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
DrugsBudigalimab·Telisotuzumab Adizutecan·Fluorouracil·Leucovorin
AbbVie
Phase 2
185
Beijing, Langfang, Harbin, Wuhan, Hangzhou
2024-12-13
Recruiting
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
NCT06959615Advanced Solid Tumor
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
334
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Langfang, Haerbin, Zhengzhou
2024-11-22
Recruiting
Comparative Effectiveness of Intervention in Multi-level Hospitals for Acute Traumatic Brain Injury(Metric-TBI)
NCT06429774Traumatic Brain Injury
Beijing Tiantan Hospital
Observational
2,000
Beijing, Baoding, Cangzhou, Chengde, Handan, Langfang, Qinhuangdao, Shijiazhuang
2024-08-01
Recruiting
Mobile Applet for Weight Management in Obese Heart Failure Patients
NCT06455878Heart Failure, Overweight and Obesity, Weight Loss, Heart Failure With Reduced Ejection Fraction
Heart Health Research Center
Not applicable
830
Beijing, Guangzhou, Langfang, Jixi, Luoyang, Shangqiu, Xinyang, Zhengzhou
2024-06-06
Active, closed
A Study of IL4Rฮฑ Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).
NCT06315426Allergic Rhinitis
DrugGR1802
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 2
240
Langfang, Xingtai, Zhengzhou, Jingzhou, Wuhan, Jinan, Liaocheng, Changzhi
2024-03-24
Recruiting
Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer
NCT05345860Early-stage Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
300
Beijing, Langfang
2022-03-24
Recruiting
CCTA Improves Clinical Management of Stable Chest Pain
NCT04691037Coronary Computed Tomography Angiography, Stable Chest Pain, Optimal Medical Therapy, Invasive Coronary Angiography
Tianjin Chest Hospital
Observational
50,000
Beijing, Langfang, Tianjin
2016-01-01
Rows per page Showing 1–35 of 35
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/langfang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 35 of those studies with a site in Langfang.

How many clinical trials are recruiting in Langfang?

23 of the 35 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 7 have not yet opened recruitment, 4 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Langfang), 35 studies
PhaseStudiesRecruitingShare
Phase 210328.6%
Phase 36417.1%
Not applicable5414.3%
Observational5414.3%
Phase 14411.4%
Phase 1/2338.6%
Phase 2/3112.9%
Phase 4102.9%

Most active sponsors

Lead sponsors with the most studies (Langfang)
Lead sponsorStudiesRecruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences42
AstraZeneca22
Beijing QL Biopharmaceutical Co.,Ltd20
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.21
Novo Nordisk A/S21
AbbVie10
Antengene Biologics Limited11
Atom Therapeutics Co., Ltd11
Beijing Anzhen Hospital11
Beijing Tiantan Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.